



(51) International Patent Classification:

A61P 31/12 (2006.01) A61P 37/06 (2006.01)
A61P 35/00 (2006.01) C07K 16/28 (2006.01)

(21) International Application Number:

PCT/US2021/014346

(22) International Filing Date:

21 January 2021 (21.01.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/963,771 21 January 2020 (21.01.2020) US

(71) Applicant: **BOLT BIOTHERAPEUTICS, INC.**
[US/US]; 900 Chesapeake Drive, Redwood City, California
94063 (US).

(72) Inventors: **ALONSO, Michael N.**; c/o Bolt Biotherapeutics,
Inc., 640 Galveston Drive, Redwood City, California
94063 (US). **DORNAN, David**; c/o Bolt Biotherapeutics,
Inc., 640 Galveston Drive, Redwood City, California

nia 94063 (US). **HENNING, Karla**; c/o Bolt Biotherapeutics,
Inc., 640 Galveston Drive, Redwood City, California
94063 (US). **KENKEL, Justin**; c/o Bolt Biotherapeutics,
Inc., 640 Galveston Drive, Redwood City, California
94063 (US). **KOWANETZ, Marcin**; c/o Bolt Biotherapeutics,
Inc., 640 Galveston Drive, Redwood City, California
94063 (US). **LEBLANC, Heidi**; c/o Bolt Biotherapeutics,
Inc., 640 Galveston Drive, Redwood City, California
94063 (US). **MALLET, William**; c/o Bolt Biotherapeutics,
Inc., 640 Galveston Drive, Redwood City, California 94063
(US).

(74) Agent: **SWANSON, Kristina L.**; Leydig, Voit & Mayer,
Ltd., Two Prudential Plaza — Suite 4900, 180 North Stetson
Avenue, Chicago, Illinois 60601-6731 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,

(54) Title: ANTI-PD-L1 ANTIBODIES




FIG. 1

(57) Abstract: The invention relates to programmed death-ligand 1 (PD-L1) binding agents, nucleic acids comprising the inventive binding agents, vectors and cells comprising the inventive nucleic acids, and compositions thereof. The invention also relates to methods of producing the inventive binding agents, methods for treating a disease, disorder, or condition in a mammal, and methods for enhancing or reducing or inhibiting an immune response in a mammal.

[Continued on next page]

ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))